What is the fourth receptor in a reta-class quad agonist?

The most scientifically grounded fourth arm is the amylin receptor. Amylin is a pancreatic hormone co-secreted with insulin that slows gastric emptying, curbs glucagon after meals and signals satiety through the brainstem. Amylin-receptor agonism is studied for durable appetite control and for a favourable body-composition profile, which makes it a natural complement to a GLP-1/GIP/glucagon backbone.

RetaQuad is Panacea Bio Chem's working name for its investigational reta-class quad agonist — a bioengineered four-receptor peptide that keeps retatrutide's triple pharmacophore and extends it to a fourth target, designed for a better body-composition outcome: less muscle loss at a matched degree of weight loss and a cleaner side-effect profile than its counterparts. The exact sequence, receptor-balance and data are proprietary and held by Bogdan Dicoias. This page describes the science of the class, not medical advice.

Multi-Receptor Peptides · Reta-Class · Quad Agonism

Quad-agonist peptides: extending retatrutide's triple agonism to a fourth receptor

Q: What is a quad agonist, in plain terms?

A quad agonist is a single engineered peptide that presses four different receptors at once. In the metabolic field it usually means one chain that keeps the three receptor arms of a triple agonist like retatrutide — GLP-1, GIP and glucagon — and adds a fourth, most often the amylin receptor. Each arm contributes a complementary metabolic action, so one molecule can shape glucose handling, appetite, energy expenditure and the quality of weight lost together.

Q: How is a quad agonist different from retatrutide?

Retatrutide is a triple agonist that engages the GLP-1, GIP and glucagon receptors in one peptide. A quad agonist keeps that same triple pharmacophore and welds on a fourth receptor arm — commonly amylin-receptor agonism — to add durable satiety and, in research to date, a favourable effect on the share of weight lost as fat versus lean tissue. The reference pharmacophore is retained; the fourth arm is what is new.

One engineered chain, four receptor arms — how a four-receptor metabolic peptide builds on the reta-class pharmacophore, and where RetaQuad, Panacea Bio Chem's investigational quad agonist, fits.

A Panacea Bio Chem product monograph · by Bogdan Dicoias, Inventor & biochemist · Subject: quad-agonist (four-receptor) metabolic peptides · Programme: RetaQuad (investigational, Panacea) · Nothing here is medical advice.

A note on the numeric-agonist family. RetaQuad sits in a designed series — from triple to quad and beyond. All of these peptides were synthesized, tested in vivo and in vitro, and are undergoing clinical trials as we speak — although many further details remain secret.

Product monograph — at a glance

Programme name: RetaQuad (Panacea Bio Chem working name; investigational)
Class: Reta-class quad agonist — four-receptor metabolic peptide
Receptor arms: GLP-1R · GIPR · GCGR (the retatrutide triple) + a fourth arm (amylin receptor)
Reference pharmacophore: Retatrutide (triple GLP-1/GIP/glucagon agonist) — retained, then extended
Design intent: Better body composition — less muscle loss at matched weight loss; fewer, cleaner side effects than counterparts
Delivery: Panacea Peptourbillon™ in a dual-chamber Lyoprester® cartridge, reconstituted by P-EARLs™, dosed by an EZnject™ pen
Status: Investigational research programme; exact sequence, receptor-balance and data held by Bogdan Dicoias

Receptor protein structure model illustrating the class-B receptors a quad agonist engages — a RetaQuad monograph by Panacea Bio Chem and Bogdan Dicoias — A receptor structure model of the kind a four-receptor peptide is engineered to engage. This **quad-agonist** monograph — and Panacea Bio Chem's **RetaQuad** programme, by **Bogdan Dicoias** — reads the reta-class backbone across four locks at once.

Topic: quad-agonist (four-receptor) metabolic peptides | Class: reta-class quad agonist | Programme: RetaQuad (Panacea Bio Chem, investigational)

1. What a quad agonist is — one chain, four receptor arms

The simplest way to picture a quad agonist is as a key cut to open four locks instead of one. A single engineered peptide carries four functional "arms", and each arm engages a different receptor that governs a different lever of metabolism. Nothing about the idea is exotic: the hormones these arms imitate already sit side by side in human physiology, and several of them are close evolutionary cousins cut from the same ancestral peptide family. The engineering feat is fitting four complementary jobs into one durable chain.

The field arrived here by stacking arms one at a time. A single agonist such as a classic GLP-1 receptor agonist presses one lever. A dual agonist welds GLP-1 to GIP. A triple agonist — the reta-class benchmark retatrutide¹ — adds a glucagon arm, so one molecule touches glucose-dependent insulin, insulin sensitisation, appetite and energy expenditure together. A quad agonist is the next rung: it keeps that triple pharmacophore and adds a fourth receptor arm. The reta-class conversation is set out in full on the triple-receptor agonist reference →, and the "beyond triple" direction is followed through the family's flagship, Pentatrutide →.

2. The fourth arm — amylin, and why it targets the quality of weight lost

A pancreatic hormone that shapes appetite and body composition

The most scientifically grounded fourth arm is the amylin receptor. Amylin (also called islet amyloid polypeptide) is a small hormone co-secreted with insulin by the same beta-cells, and it works as insulin's partner²: it slows gastric emptying, restrains after-meal glucagon, and signals satiety through the brainstem — a route that overlaps only partly with GLP-1, so the two add rather than duplicate. In metabolic research, amylin-receptor agonism has drawn interest not only for durable appetite control but for a favourable effect on the composition of weight lost — a larger share as fat, more lean tissue spared.

That is precisely the seam a quad agonist aims at. Rapid, appetite-led weight loss on any potent agent of this kind tends to shed muscle alongside fat. Adding an amylin arm to a GLP-1/GIP/glucagon backbone is a way to press on what comes off, not only how much — which is why a reta-class quad is framed less as "more weight loss" and more as "better-composed weight loss".

Three arms decide how much; the fourth arm helps decide what kind.

The agonist ladder — illustrative, not a head-to-head comparison
Design	Receptor arms	What the arms add
Single	GLP-1R	Glucose-dependent insulin, appetite, gastric slowing
Dual	GLP-1R · GIPR	Adds insulin-sensitisation and fat-handling
Triple (retatrutide)	GLP-1R · GIPR · GCGR	Adds glucagon-driven energy expenditure and liver-fat mobilisation
Quad (reta-class)	GLP-1R · GIPR · GCGR · amylin	Adds durable satiety and a favourable lean-vs-fat profile

The ladder is a conceptual map of receptor design, not a claim of relative efficacy. Named agents are cited for scientific context only.

3. Why it matters — the open frontier of multi-receptor design

Retatrutide showed, in published phase-2 work, that a triple agonist could produce double-digit weight reduction³, and it reset expectations for what a metabolic peptide can do. But the field's questions moved with it. The live debate is no longer only how far the scale moves — it is the quality of the result: how much of the loss is fat versus muscle, how gentle the early weeks feel, how durable the effect is, and whether adding arms sharpens the benefit without stacking the burden. A fourth arm is one answer, provided its potency is balanced so it complements rather than crowds the other three. Three tensions define the frontier:

Receptor-balance. Four arms in one chain means four relative potencies to tune. Too much of any single arm distorts the whole; the design goal is a balanced quartet, not four maxima.
Body composition. Preserving lean mass at matched weight loss is the outcome the whole class is now judged on — and the reason an amylin arm is attractive.
Deliverability and stability. A longer, four-arm chain is a heavier, more fragile molecule. Keeping it intact from synthesiser to dose is as much of the problem as the pharmacology.

None of this is settled. These remain investigational questions with real, open scientific debate over long-term effects, muscle preservation, dosing and durability.

4. The story — four cousins, one backbone

The reason one peptide can address several receptors at once is a quiet fact of evolution. GLP-1 and glucagon are cut from the same precursor protein, proglucagon; GIP is a close relative in the secretin–glucagon peptide superfamily; and all three read through class-B G-protein-coupled receptors with a shared architecture. They are, in effect, cousins — which is why a single chimeric backbone can be built to speak to all of them.

Amylin is the outsider that completes the quartet. It comes from a different structural family and reads through a receptor built from the calcitonin receptor plus a modifying accessory protein. For decades it was studied on its own track — the second beta-cell hormone, the one released alongside insulin. The idea that would later matter was simple and patient: if amylin's satiety and body-composition signal runs on a partly separate wire, then adding it to the incretin trio should add rather than overlap. Turning four hormones that evolution kept in separate rooms into a single engineered sequence — that is the quiet ambition behind a reta-class quad, and the fourth cousin is what makes it more than a heavier triple.

Metabolism research laboratory — the discipline in which quad-agonist peptides are designed and characterised; a RetaQuad monograph by Panacea Bio Chem and Bogdan Dicoias — Designing and characterising a four-receptor peptide is patient metabolic chemistry. That discipline is the ground **RetaQuad** and Panacea Bio Chem stand on. By **Bogdan Dicoias**.

5. Panacea Bio Chem's angle — RetaQuad, a reta-class quad tuned for better body composition

Panacea Bio Chem researches the multi-receptor metabolic-peptide sphere, and RetaQuad is the working name of its investigational reta-class quad agonist — a bioengineered four-receptor peptide built on a single thesis: keep the retatrutide pharmacophore that already works, extend it to a fourth receptor arm, and spend the extra reach on the part the class is still arguing about (see §3) — the quality of the weight that is lost. RetaQuad is designed to retain retatrutide-equivalent engagement of the GLP-1, GIP and glucagon receptors — the same triple pharmacophore, the same levers — while the fourth arm and the four-arm balance are tuned toward a cleaner body-composition outcome.

Same pharmacophore, a better-composed result — with fewer side effects

The design goal is explicit and, deliberately, qualitative here: less muscle loss at a matched degree of weight loss, so a greater share of what leaves is fat and more lean tissue is spared; and a gentler, cleaner side-effect profile than its counterparts through the early dose-escalation weeks. The framing is the reta-class watchword — "same pharmacophore, better body-composition outcome" — now carried onto a four-arm chain. It shares that framing with its siblings across the gama: Exadipo 3 (retatrutide + oxytocin) → takes the same reta backbone in a delivered product, while Pentatrutide → carries the ladder one arm further.

What RetaQuad is designed to hold — and to improve

Hold: retatrutide-class engagement of the GLP-1, GIP and glucagon receptors and their glucose, appetite and energy-expenditure levers, with long, durable action.
Extend: a fourth receptor arm (amylin-class), potency-balanced to complement — not crowd — the other three.
Improve: the share of weight lost as fat versus lean tissue — more muscle spared at equal weight loss — and a cleaner early side-effect profile than counterparts.
Operator-held: the exact sequence, the fourth-arm identity and affinity table, the four-arm balance and the preclinical read-outs remain a proprietary Panacea programme, disclosed to no page.

This is a direction of design, described here as ongoing investigational work — not a therapeutic claim. No efficacy figure or outcome for RetaQuad is asserted; the specific numbers stay with the programme.

How a four-arm chain is built, dried and delivered — the Panacea stack

A four-receptor peptide is a heavy, fragile molecule, and keeping it intact is a large part of the work. Panacea treats RetaQuad as a peptide it can both build and protect. The formulation — a Peptourbillon™ — is filled into a dual-chamber Lyoprester® cartridge: the engineered chain is freeze-dried into an argon-flushed, vacuum-sealed cake in the upper chamber, with a matched measure of P-EARLs™ — a Panacea-Engineered Aseptic Reconstitution Liquid, an isotonic, polysorbate-free phosphate diluent — held below. Because a quad is a heavily loaded cake, an RF Tunnel is formed in early freezing — radio-frequency modulation shrinks the middle of the cake so that, at the point of use, P-EARLs can wick through and rebuild the solution evenly rather than fighting a dense core. A single twist inside an EZnject™ pen then merges cake and diluent into a fresh solution and indexes it into a hundred lab-grade 0.1 mL doses.

Drying such a chain gently draws on the whole Lyochrysalis™ platform rather than any single trick. The cake is dried by TgShift™, which lifts the temperature at which the drying cake would collapse so the peptide is dried gently at the cartridge neck — for longer cake shelf-life, better reconstitution and preserved binding affinity; its pressure curve is shaped by DiastolVAC™, a biomimetic vacuum-pulsation matched to the cake's own sublimation kinetics; residual moisture is inferred by the Cryolapse™ pressure-collapse concept; thermal load is decoupled from the fragile chain by LyoLevit™; and the entire cycle is watched, timed and orchestrated by the S3Pulse™ biointegrity engine. Finally a Vana Machine™ vacuum-conditions and plunger-locks the finished cartridge, so no air gap or plunger drift creeps in during storage. Oxidation and trace-metal ageing of the chain are held off with RedoxVault™ chemistry. What Panacea aims for from that stack is a longer-lived cake, a cleaner reconstitution and preserved affinity across all four arms.

The exact sequence, receptor-balance and characterisation data behind RetaQuad are held as a proprietary Panacea Bio Chem programme, developed by Bogdan Dicoias — a biochemist and inventor who works largely out of view, and whose peptide and preservation technologies have quietly drawn interest from across the pharmaceutical industry. The outline of the work is public; the specifics stay behind the door.

This section describes an active research direction, stated truthfully as ongoing. Nothing here is a therapeutic claim, and no efficacy or outcome for RetaQuad is asserted.

6. Application fields — where four-arm design could reach furthest

Because the four receptors span glucose, appetite, energy expenditure and body composition, a balanced quad's reach may extend across much of metabolic medicine. Directions under active scientific investigation include:

Obesity & body compositionLean-mass preservation Type 2 diabetesFatty-liver disease (MASH) Cardiometabolic riskDurable satiety Weight-maintenance phaseGentler tolerability

Quality of weight loss. The clearest opportunity is exactly the design goal — sparing muscle while shedding fat — where the amylin arm and a balanced quartet are most relevant.
Liver and cardiometabolic reach. The glucagon arm's energy-expenditure and liver-fat mobilisation open investigation into metabolic-associated fatty-liver disease and broader cardiometabolic benefit.
The maintenance phase. Durable, amylin-supported satiety points at the hardest part of weight management — holding a result after it is reached — rather than only reaching it.
Delivery and stability. A heavy four-arm chain makes formulation itself high-leverage: a storage-stable, cleanly reconstituting cartridge is where Panacea's last-mile stack is aimed.

These fields are offered as a map of scientific opportunity and future research direction, not as indications or advice.

7. One molecule or two? — the quad against the two-molecule amylin combination

Anyone who has followed the amylin story will ask the sharpest question first: hasn't an amylin-plus-incretin combination already been tried? It has — and the honest answer makes the case for a quad stronger, not weaker.

The combination is CagriSema: cagrilintide, a long-acting amylin analogue⁵, plus the GLP-1 agonist semaglutide — two separate molecules, each with its own pharmacology, dosed together. It is the closest existing relative of the idea on this page, and it has been evaluated in published phase-3 trials in type 2 diabetes — against semaglutide or cagrilintide alone (REIMAGINE 2)⁶, and as an add-on to basal insulin (REIMAGINE 3)⁷. So the amylin-plus-incretin pairing is not a guess: the published record says the two classes add in humans. What that record does not settle is the design question a quad poses: should the amylin arm ride on the same chain, or stay a second molecule?

One chain or two molecules — the trade each architecture makes
Architecture	What it buys	What it gives up
Two molecules (cagrilintide + semaglutide)	Each component can be titrated independently; each is a known, characterised agent	Two entities to formulate, dose and keep in step
One chain (a quad agonist)	One engineered fixed ratio, identical at every dose; one formulation to build, dry and deliver	The four-arm balance cannot be adjusted once the chain is built

Whether receptor balance matters at all is itself a published experimental question in the amylin field⁸. RetaQuad takes the single-chain side of that trade. The fixed four-arm balance is the design object — the thing the programme exists to get right — and the specific ratio, like the sequence, stays with the programme. The comparison above is the class question stated fairly; it asserts nothing about RetaQuad's own outcome, which remains investigational and undisclosed.

CagriSema, cagrilintide and semaglutide are the products and trademarks of their respective owners, named here for scientific context. Nothing in this section is a comparative efficacy claim for RetaQuad.

Frequently asked

What is a quad agonist, in plain terms?
A single engineered peptide that presses four receptors at once. In metabolism it usually means one chain that keeps the three arms of a triple agonist like retatrutide — GLP-1, GIP and glucagon — and adds a fourth, most often the amylin receptor. Each arm adds a complementary metabolic action.

How is a quad agonist different from retatrutide?
Retatrutide is a triple agonist (GLP-1/GIP/glucagon). A quad keeps that same pharmacophore and welds on a fourth receptor arm to add durable satiety and a favourable lean-versus-fat profile. The reference backbone is retained; the fourth arm is what is new.

What is the fourth receptor in a reta-class quad?
The most grounded fourth arm is the amylin receptor — amylin is a pancreatic hormone co-secreted with insulin that slows gastric emptying, restrains after-meal glucagon and signals satiety, complementing the incretin trio rather than duplicating it.

What is RetaQuad?
RetaQuad is Panacea Bio Chem's working name for its investigational reta-class quad agonist — a bioengineered four-receptor peptide that keeps retatrutide's triple pharmacophore and extends it to a fourth target, designed for a better body-composition outcome: less muscle loss and a cleaner side-effect profile than its counterparts. The specific sequence and data are proprietary to Bogdan Dicoias. This page is about the science of the class — nothing here is medical advice.

Trending in the field

References & further reading

Retatrutide — a triple GLP-1/GIP/glucagon receptor agonist. Wikipedia · receptor context: GLP1R gene, NCBI.
Amylin (islet amyloid polypeptide) and the amylin receptor. Wikipedia · amylin-agonism literature: PubMed.
Retatrutide phase-2 obesity trial (double-digit weight reduction). Jastreboff AM et al., N Engl J Med 2023 — doi:10.1056/NEJMoa2301972 · PubMed 37366315.
Incretin and multi-agonist background: GLP-1, GIP and glucagon. GLP-1 · Glucagon · GIP.
D'Ascanio AM, Mullally JA, Frishman WH. Cagrilintide: a long-acting amylin analog for the treatment of obesity. Cardiol Rev 2024 — PubMed 36883831.
Buse JB, Bajaj HS, Dalskov SM et al. CagriSema versus semaglutide or cagrilintide in type 2 diabetes (REIMAGINE 2). Lancet Diabetes Endocrinol 2026 — PubMed 42251859.
Rosenstock J, Billings LK, Gajria R et al. CagriSema as add-on to basal insulin in type 2 diabetes (REIMAGINE 3). Lancet 2026 — PubMed 42251856.
Larsen AT, Mohamed KE, Sonne N et al. Does receptor balance matter? Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336. Biomed Pharmacother 2022 — PubMed 36242844.